Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Benjamin Miron, MD, Fox Chase Cancer Center

Videos

Immune Checkpoint Inhibitors Following Platinum Chemotherapy Regimens in Urothelial Carcinoma

10/17/2022

Benjamin Miron, MD, discusses a study comparing survival on single-agent immune checkpoint inhibitors in the second-line treatment setting, following either cisplatin or carboplatin, in patients with urothelial carcinoma.

Benjamin Miron, MD, discusses a...

10/17/2022

Oncology

Simon Crabb, PhD, MBBS, University of Southampton

Videos

Maintenance Rucaparib Following Chemotherapy for DNA Repair Deficiency Biomarker-Positive Urothelial Carcinoma

09/29/2022

Simon Crabb, PhD, MBBS, reviews results from a randomized, double-blind phase 2 trial of maintenance rucaparib following chemotherapy in DNA repair deficiency biomarker-positive patients with metastatic urothelial carcinoma.

Simon Crabb, PhD, MBBS, reviews...

09/29/2022

Oncology

Quiz

Enfortumab Vedotin Plus Pembrolizumab for Urothelial Cancer

09/27/2022

In an analysis of Cohort K from the EV-103 trial evaluating enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, did that the combination therapy have an objective...

In an analysis of Cohort K from...

09/27/2022

Oncology

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center

VIDEOS

Enfortumab Vedotin Plus Pembrolizumab Induces High Response Rates in Cisplatin-Ineligible Patients With Urothelial Cancer

09/20/2022

Allison Casey

Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.

Jonathan Rosenberg, MD, reviews...

09/20/2022

Oncology

Quiz

Quiz: Pembrolizumab Plus Sacituzumab Govitecan in Platinum-Refractory Metastatic Urothelial Cancer

07/21/2022

True or False: Combination pembrolizumab and sacituzumab govitecan demonstrated a clinical benefit among patients with platinum-refractory metastatic urothelial cancer.

True or False: Combination...

07/21/2022

Oncology

Petros Grivas, MD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab Yields Encouraging Response Rates in Metastatic Urothelial Cancer

06/22/2022

Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Petros Grivas, MD, shares...

06/22/2022

Oncology

Podcasts

Maintenance Therapy With Cabozantinib Shows No Significant Benefit vs Placebo for Metastatic Urothelial Carcinoma

06/21/2022

Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.

Robert Jones, MD, shares results...

06/21/2022

Oncology

Joseph Jacob, MD, SUNY Upstate University Hospital

Podcasts

Joseph Jacob, MD, Reviews SunRISe-1 Trial Progress in High-Risk, Non–Muscle-Invasive Bladder Cancer

03/02/2022

Dr Jacob highlights the progress of SunRISe-1: a phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non–muscle-invasive bladder cancer unresponsive to BCG who are ineligible for or...

Dr Jacob highlights the progress...

03/02/2022

Oncology

Bishoy Faltas, MD, Weill Cornell Medicine

Videos

Serial ctDNA Analysis Predicts Clinical Progression, Guides Precision Medicine in Advanced Urothelial Carcinoma

02/17/2022

Bishoy Faltas, MD, discusses targeted sequencing of circulating tumor DNA (ctDNA) to monitor changes in the variant allele frequencies of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma.

Bishoy Faltas, MD, discusses...

02/17/2022

Oncology

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

The Importance of a Multidisciplinary Approach to Bladder Cancer

11/23/2021

Petros Grivas, explains the importance of a multidisciplinary tumor board when reviewing the treatment options for patients with bladder cancer.

Petros Grivas, explains the...

11/23/2021

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology